VisiJet introduces HydroKeratome at the European Society of Cataract and Refractive Surgeons -ESCRS- Meeting.Business Editors/Health/Medical Writers IRVINE, Calif.--(BUSINESS WIRE)--Aug. 29, 2003 Showing and Events at Meeting Expected to Maximize International Awareness and Sales VisiJet Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :VJET), developers of innovative technologies for the ophthalmic surgical market, will introduce their initial product, the HydroKeratome(R) Waterjet System at the ESCRS ESCRS European Society of Cataract and Refractive Surgeons meeting in Munich Germany, September 6-10, 2003. Hands-on "wet labs" will be provided for surgeons to actually perform surgical cuts using the new technology that utilizes a high-pressure micro beam of water to cut issue. VisiJet medical and support personnel will provide educational and technical information. In addition, sales management and distributors representing countries across the world will be in attendance to take orders. VisiJet distributors who will be at the meeting and the areas they cover include: New Tech SpA -- Italy; W.M. Bloss, S.A. -- Spain; Medillas AG -- Switzerland; Kestrel kestrel Any of several birds of prey (genus Falco) known for hovering while hunting. Kestrels prey on large insects, birds, and small mammals. The male is more colourful than the female. Kestrels are mainly Old World birds, but one species, the American kestrel (F. Ophthalmolics -- United Kingdom; Tradis Gat Ltd. -- Israel; Ioltechnologie -- France; Ophtec BV -- Holland; Polytech Ophthalmology GmbH -- Germany; Medicals International SARL SARL South African Radio League SARL Société Anonyme à Responsabilité Limitée (French: limited liability company) SARL Salem Animal Rescue League (Salem, NH) SARL Sociedade Anónima de Responsabilidade Limitada -- Lebanon. "ESCRS is the largest and most important international meeting in ophthalmology and represents an excellent opportunity to demonstrate to surgeons from around the world the benefits of our new waterjet technology," said Randy Bailey, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of VisiJet. "This is the first opportunity for surgeons to personally experience the precision and ease of the device and we anticipate the results will be positive. Refractive refractive capacity to refract light. refractive error a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. surgeons have long told us they want something better than current mechanical microkeratomes and now it's here." About VisiJet Inc. Visijet is a medical device company based in Irvine, focused on the development and marketing of innovative ophthalmic applications that will result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. VisiJet's lead products, the HydroKeratome(R) and Pulsatome(R), utilize the company's proprietary and patented waterjet technology that uses a high-pressure micro beam of water the diameter of a human hair to cut ocular tissue. The FDA-approved HydroKeratome(R), uses the waterjet technology to cut the cornea cornea: see eye. as required in LASIK LASIK laser-assisted in-situ keratomileusis. LA·SIK n. Eye surgery in which the surface of the cornea is reshaped using a laser, performed to correct certain refractive disorders such as myopia. surgery. The Pulsatome(R), currently under development, is a device that uses waterjet technology to remove cataracts -- the most performed surgical procedure in the world. VisiJet is located at 192 Technology Drive, Suite Q, Irvine, CA., phone 949-450-1660, fax 949-453-9652, Investor Relations Investor relations The process by which the corporation communicates with its investors. 949-450-1660 Ext. 26, and Web site www.visijet.com. Forward-Looking Statements Except for historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Securities Exchange Act that involve risks and uncertainties that could cause actual results to differ materially from those expressed. These matters include, but are not limited to, information about the company's technologies and products, financial situations, or business opportunities. This news release shall not constitute an offer to sell or the solicitation of an offer to sell any of these securities. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion